Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enkastim
- Development stage
- Unknown
- Lead developer
- Multimmune
- Modality
- Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ENKASTIM is an autologous natural killer (NK) cell therapy designed to treat cancers that express membrane-bound heat shock protein 70 (mHsp70), a tumor-specific biomarker highly expressed on aggressive cancer cells but not on normal cells. The therapy involves collecting a patient's peripheral blood mononuclear cells (PBMCs) via leukapheresis and activating them ex vivo with a patented Hsp70-derived synthetic peptide (TKD) and low-dose interleukin-2 (IL-2). These activated NK cells are then reinfused into the patient to target and kill mHsp70-positive tumor cells. No genetic modification of the NK cell product is required. Clinical trials have shown promising safety and efficacy signals in advanced non-small cell lung cancer (NSCLC) and colorectal cancer patients. The primary developer is Alphageneron Pharmaceuticals, with multimmune GmbH also involved in development[1][3][5][6][7].
- Brand names
- ENKASTIM
- Other names
- ENKASTIMTKD activated natural killer cellsENKASTIM-evENKASTIM-iv
Beyond the preview
Go deeper on enkastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enkastim.